ADMA Biologics Inc (ADMA) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for ADMA Biologics Inc, updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Price
$11.28
+0.98% today
Market cap
$2.5B
Overall quality
72/100
Kronos AI 30-day
−18.6%
0 of 8 simulated paths end higher
ADMA Biologics Inc (ADMA) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $2.5B. It trades at $11.28, up 0.98% today, at 15 times earnings. Its overall quality score is 72 out of 100, ranked against the whole US market. 2 analysts' average target of $15.00 implies +33.0% from today's price. Kronos AI's 30-day forecast is −18.6% (0 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $15.00 |
| Low – high | $12.00 – $18.00 |
| Analysts | 2 |
| Upside to average | +33.0% |
Kronos AI 30-day forecast
| Expected close | $9.09 (−18.6%) |
| Likely range | −26.5% … −17.2% |
| As of | 2026-10-27 |
0 of 8 simulated paths end higher.
Quality scores
| Profitability | 85 |
| Solvency | 54 |
| Growth | 78 |
| Overall | 72 |
| P/E | 15 |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Biological Products (No Diagnostic Substances)
For information only, not investment advice. Prices updated: 2026-10-29.